Aims and Scope
Comprehensive coverage across all domains of cancer research and clinical oncology.
Defining the Frontiers of Cancer Science
Journal of Neoplasms publishes mechanistic, translational, and clinical research that advances understanding of cancer biology, improves diagnostic precision, and transforms therapeutic outcomes. Our scope spans from molecular discovery to patient care.
We prioritize research with clear translational potential and clinical impact.
Tumor Biology
- Cancer genomics and epigenetics
- Oncogene and tumor suppressor pathways
- Tumor microenvironment dynamics
- Metastasis and invasion mechanisms
- Cancer stem cell biology
- Drug resistance mechanisms
Treatment Innovation
- Immunotherapy and checkpoint inhibitors
- CAR-T and cellular therapies
- Targeted molecular agents
- Antibody-drug conjugates
- Combination treatment strategies
- Overcoming therapeutic resistance
Patient Outcomes
- Clinical trial design and results
- Precision oncology approaches
- Biomarker-driven treatment
- Survivorship and quality of life
- Palliative and supportive care
- Health equity in oncology
Solid Tumors
Breast, lung, colorectal, prostate, pancreatic, liver, kidney, bladder, ovarian, gastric, esophageal, head and neck, melanoma, and brain tumors.
Hematologic Malignancies
Leukemias (AML, ALL, CML, CLL), lymphomas (Hodgkin, non-Hodgkin), multiple myeloma, myelodysplastic syndromes, and other blood cancers.
Rare and Pediatric Cancers
Sarcomas, neuroendocrine tumors, thyroid cancers, childhood malignancies, and rare tumor subtypes requiring specialized research attention.
Diagnostics and Biomarkers
Liquid biopsy technologies, molecular imaging, early detection markers, companion diagnostics, and prognostic indicators.
Translational Focus: JN particularly encourages manuscripts that bridge laboratory discoveries with clinical applications. Research spanning basic cancer biology, preclinical models, and clinical validation advancing patient outcomes is highly valued.
Original Research
Novel findings in cancer biology, therapeutics, or clinical outcomes with rigorous methodology (5,000-8,000 words).
Reviews and Meta-Analyses
Comprehensive syntheses of current knowledge or systematic evidence analyses (6,000-10,000 words).
Clinical Trial Reports
Phase I-IV trial results, interim analyses, and long-term follow-up studies.
Short Communications
Rapid reports of significant findings warranting immediate dissemination (2,000-3,000 words).
Submit Your Cancer Research
Contribute to the global effort advancing cancer diagnosis and treatment.
